https://www.businesswire.com/news/home/20211104005348/en/Sangamo-Therapeutics-Announces-Preliminary-Phase-12-Data-Showing-Tolerability-and-Sustained-Elevated--Gal-A-Enzyme-Activity-in-Patients-With-Fabry-Disease
Sangamo Therapeutics Announces Preliminary Phase 1/2 Data Showing Tolerability and Sustained...
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced preliminary results from the Phase 1/2 STAAR clinical study evaluating...
sangamo therapeuticspreliminary phase1 2
https://www.fiba.basketball/en/history/178-fiba-afrobasket-qualifiers/208167/teams/chad
Chad - FIBA Afrobasket 2021 - Preliminary Phase | FIBA Basketball Events
fiba afrobasket 2021preliminary phasechadbasketballevents
https://www.biospace.com/sophiris-bio-reports-encouraging-preliminary-data-from-phase-2a-proof-of-concept-study-in-localized-prostate-cancer
Sophiris Bio Reports Encouraging Preliminary Data From Phase 2a Proof Of Concept Study In Localized...
https://www.jnj.com/media-center/press-releases/updated-results-from-the-phase-1-study-of-the-bcmaxcd3-bispecific-teclistamab-show-preliminary-efficacy-in-patients-with-heavily-pretreated-relapsed-or-refractory-multiple-myeloma
Updated Results from the Phase 1 Study of the BCMAxCD3 Bispecific Teclistamab Show Preliminary...
Nov 16, 2025 - First-reported results for the subcutaneous formulation and updated results for the intravenous formulation presented at ASH 2020
phase 1 study
https://www.fiba.basketball/en/history/308-fiba-womens-eurobasket-division-c/103/games/2072-SCO-AND
Scotland vs Andorra - Group Phase - European Promotion Cup for Women - Preliminary Round | FIBA...
Explore boxscore and game stats of Scotland and Andorra (Group Phase) - European Promotion Cup for Women - Preliminary Round
https://www.businesswire.com/news/home/20260326810310/en/Rubedo-Life-Sciences-Announces-Positive-Preliminary-Phase-1-Clinical-Trial-Results-for-Lead-Drug-Candidate-RLS-1496-in-Patients-with-Plaque-Psoriasis-Atopic-Dermatitis-and-Skin-Aging?_gl=1*z5pgy4*_gcl_au*OTAxNzMzNjMxLjE3NzAxNjAxMjU.*_ga*ODk1ODUyNjA5LjE3NzAxNjAxMjU.*_ga_ZQWF70T3FK*czE3NzQ1MjgyNDAkbzEwJGcxJHQxNzc0NTI4MjY3JGozMyRsMCRoMA
Rubedo Life Sciences Announces Positive Preliminary Phase 1 Clinical Trial Results for Lead Drug...
Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medic...
phase 1 clinical trial
https://www.eib.org/en/registers/all/87173280
E-80 HIGHWAY NIS-MERDARE PHASE I - Preliminary Design and Feasibility Study
phase i
https://stockhouse.com/news/press-releases/2017/01/18/kalytera-therapeutics-announces-preliminary-results-of-a-phase-2a-clinical
2017-01-18 | Kalytera Therapeutics Announces Preliminary Results of a Phase 2a Clinical Study in...
(2017-01-18 | EXPM:KALY) Kalytera Therapeutics Announces Preliminary Results of a Phase 2a Clinical Study in the Prevention of Graft versus Host Disease
https://www.biospace.com/wilson-therapeutics-release-promising-preliminary-long-term-data-from-wtx101-phase-ii-extension-study-to-be-presented-at-b-aasld-annual-meeting-b
Wilson Therapeutics Release: Promising Preliminary Long-Term Data From WTX101 Phase II Extension...
https://investingnews.com/adicet-bio-announces-positive-preliminary-data-from-adi-001-phase-1-study-in-patients-with-lupus-nephritis-and-systemic-lupus-erythematosus/
Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus...
Oct 7, 2025 - -Clinical data to date supports a potentially transformational approach to treating autoimmune diseases with an off-the-shelf, one-time therapy- -As of the...
https://www.eib.org/de/registers/all/87173280
E-80 HIGHWAY NIS-MERDARE PHASE I - Preliminary Design and Feasibility Study
phase i
https://www.sciencedaily.com/releases/2008/03/080317090122.htm
Improved Foam For Varicose Veins Found To Be Safe In Preliminary Results From Phase II Trial |...
A small group of patients with a common heart defect who were treated for varicose veins with an injectable microfoam experienced no neurological, visual or...
https://www.ehu.eus/es/web/biography-parliament/-/making-waves-conceiving-layers.-geophysics-industry-and-realism-1918-1960.-preliminary-phase.-1
Making Waves, Conceiving Layers. Geophysics, Industry and Realism, 1918-1960. Preliminary Phase. -...
making waves
https://www.prnewswire.com/news-releases/daiichi-sankyo-presents-preliminary-phase-1-data-for-trop2-targeting-adc-ds-1062-in-patients-with-non-small-cell-lung-cancer-at-2019-asco-annual-meeting-300860250.html
Daiichi Sankyo Presents Preliminary Phase 1 Data for TROP2 Targeting ADC DS-1062 in Patients with...
/PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that preliminary results from the dose escalation part of a phase 1...
https://www.seattlechildrens.org/research/research-studies-clinical-trials/current-studies/all/pepn2415-a-phase-i-study-to-assess-the-safety-tolerability-pharmacokinetics-and-preliminary-efficacy-of-azd1390-nsc-852149-ind-172675-when-combined-with-focal-radiation-in-pediatric-patients-with-high-grade-glioma-study00005498/
PEPN2415, A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary...
This study aims to improve the outcomes for patients with HGGs, including DIPG, which currently have dismal survival rates and are resistant to...
phase i study
https://www.ehu.eus/en/web/biography-parliament/-/making-waves-conceiving-layers.-geophysics-industry-and-realism-1918-1960.-preliminary-phase.-2
Making Waves, Conceiving Layers. Geophysics, Industry and Realism, 1918-1960. Preliminary Phase. -...
making waves
https://www.prnewswire.com/news-releases/maxcyte-to-share-preliminary-phase-i-data-on-mcy-m11-at-asco-2020-annual-meeting-301060478.html
MaxCyte to Share Preliminary Phase I Data on MCY-M11 at ASCO 2020 Annual Meeting
/PRNewswire/ -- MaxCyte, the global clinical-stage cell-based therapies and life sciences company, announces that clinical data from the first three cohorts...
https://www.biospace.com/vaxart-announces-positive-preliminary-data-from-phase-1-clinical-trial-evaluating-its-oral-covid-19-tablet-vaccine-candidate
Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19...
Feb 3, 2021 - Vaxart, Inc., (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines administered by tablet, today announced preliminary data from its...
https://www.biospace.com/genmab-a-s-announces-preliminary-results-in-phase-2-study-of-daratumumab-in-double-refractory-multiple-myeloma
Genmab A/S Announces Preliminary Results In Phase 2 Study Of Daratumumab In Double Refractory...
https://www.ehu.eus/eu/web/biography-parliament/-/making-waves-conceiving-layers.-geophysics-industry-and-realism-1918-1960.-preliminary-phase.
Making Waves, Conceiving Layers. Geophysics, Industry and Realism, 1918-1960. Preliminary Phase. -...
making waves
https://www.biospace.com/deciphera-pharmaceuticals-presents-preliminary-data-from-phase-1b-2-study-of-rebastinib-in-combination-with-paclitaxel-in-patients-with-advanced-endometrial-cancer-at-the-asco-2020-virtual-scientific-program
Deciphera Pharmaceuticals Presents Preliminary Data from Phase 1b/2 Study of Rebastinib in...
May 29, 2020 - Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced the presentation of data from the endometrial cancer cohort of Part 2 of its ongoing Phase 1b/2...
https://www.biospace.com/kronos-bio-presents-positive-preliminary-data-from-phase-1-dose-escalation-portion-of-phase-1-2-kb-0742-study-at-aacr-nci-eortc
Kronos Bio Presents Positive Preliminary Data from Phase 1 Dose Escalation Portion of Phase 1/2...
Oct 13, 2023 - Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced positive preliminary data from the...
https://www.merck.com/news/ridgeback-biotherapeutics-and-merck-announce-preliminary-findings-from-a-phase-2a-trial-of-investigational-covid-19-therapeutic-molnupiravir/
Ridgeback Biotherapeutics and Merck Announce Preliminary Findings from a Phase 2a Trial of...
Apr 17, 2026 - The findings reported on a secondary objective to reduce time to negativity of infectious SARS-CoV-2 virus isolation from nasopharyngeal swabs from...
https://www.prnewswire.com/news-releases/nuvalent-to-present-preliminary-data-from-alkove-1-phase-12-clinical-trial-of-nvl-655-at-35th-aacr-nci-eortc-symposium-301930021.html
Nuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 at 35th...
/PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically...
https://www.biospace.com/medimmune-inc-release-preliminary-data-from-caiv-t-pivotal-phase-3-trial-demonstrate-clinical-efficacy-over-flu-shot-in-head-to-head-influenza-stud
MedImmune, Inc. Release: Preliminary Data From CAIV-T Pivotal Phase 3 Trial Demonstrate Clinical...